eNauczanie

Since 2022, the active ingredient semaglutide has been approved in the EU by the European Medicines Agency under the trade name Wegovy for the treatment of severe obesity. It has a dosage more than twice as high as Ozempic. Wegovy can be prescribed for a body mass index (BMI) of 30, or for concomitant diseases such as diabetes or high blood pressure with a BMI of 27 or more. The weight loss injection from the Danish manufacturer Novo Nordisk has been available in Germany since mid-July 2023. Wegovy has been classified as a lifestyle drug by the Federal Joint Committee. The costs are not covered by health insurance companies.

The even more effective active ingredient tirzepatide from the USA has now also been approved for the treatment of obesity under the name Mounjaro, but only for those affected aged 18 and over. It combines the active principle of semaglutide with another active principle and thus achieves around 50 percent more weight loss than semaglutide. The pharmaceutical industry is also researching other drugs with similar active ingredients.